US-headquartered trial services firm MakroCare has continued
its expansion in Asia with a new partnership with South Korea-based CRO LSK
Global, according to Outsourcing-Pharma.
The deal, financial terms of which have not been disclosed, will see the firms
provide client and promotional support for drug development, trial management
and commercialization services in their respective territories.
MakroCare president Mahesh Malneedi told Outsourcing-Pharma that a key motivation for the
collaboration was supporting the firm's activities in Asia, particularly in the
world's second biggest pharmaceutical
market Japan where it has operated for the past two years.
"For Asian trials that need to be submitted to Japan, where PMDA accepts
data mostly from Japan, Korea, Taiwan and China, we need other countries data
to support our Japanese operations," said Malneedi.
Beyond Japan Malneedi said teaming with LSK gives access to Korea and Taiwan
which he called "very good markets for high-end products in pharma,
biotech and devices where we are seeing more interest in doing trials by
multi-nationals as part of product extension strategy."
